Immuneering (IMRX) Equity Average (2021 - 2024)
Historic Equity Average for Immuneering (IMRX) over the last 4 years, with Q3 2024 value amounting to $62.0 million.
- Immuneering's Equity Average fell 4339.85% to $62.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $62.0 million, marking a year-over-year decrease of 4339.85%. This contributed to the annual value of $100.2 million for FY2023, which is 2460.36% down from last year.
- Latest data reveals that Immuneering reported Equity Average of $62.0 million as of Q3 2024, which was down 4339.85% from $72.5 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Equity Average registered a high of $157.1 million during Q4 2021, and its lowest value of $61.6 million during Q3 2021.
- Its 4-year average for Equity Average is $106.7 million, with a median of $106.4 million in 2023.
- Per our database at Business Quant, Immuneering's Equity Average soared by 10753.19% in 2022 and then tumbled by 4339.85% in 2024.
- Quarter analysis of 4 years shows Immuneering's Equity Average stood at $157.1 million in 2021, then dropped by 26.26% to $115.9 million in 2022, then decreased by 16.03% to $97.3 million in 2023, then plummeted by 36.26% to $62.0 million in 2024.
- Its Equity Average stands at $62.0 million for Q3 2024, versus $72.5 million for Q2 2024 and $84.6 million for Q1 2024.